Real-world study of use patterns and clinical outcomes for patients with myelodysplastic syndrome initiating oral decitabine and cedazuridine or intravenous/subcutaneous hypomethylating agents
Background: Decitabine and cedazuridine (DEC-C) is the only oral hypomethylating agent (HMA) approved for myelodysplastic syndromes (MDS) in the United States. The other HMAs approved for MDS, decitabine and azacitidine, are administered intravenously (IV) or subcutaneously (SC). Objectives: This st...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publishing
2026-02-01
|
| シリーズ: | Therapeutic Advances in Hematology |
| オンライン･アクセス: | https://doi.org/10.1177/20406207261421326 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|